Related Experiment Video
Updated: Apr 8, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.8K
Modelling hepatitis C therapy--predicting effects of treatment
Alan S Perelson1, Jeremie Guedj2
1Theoretical Biology and Biophysics, MS-K710, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Nature Reviews. Gastroenterology & Hepatology
|July 1, 2015
Summary
Mathematical modeling of Hepatitis C virus (HCV) RNA levels reveals insights into viral dynamics and treatment efficacy. This approach helps estimate viral production, drug resistance, and optimal therapy duration for curing HCV infection.
Area of Science:
- Virology
- Mathematical Biology
- Pharmacokinetics
Background:
- Mathematical modeling of Hepatitis C virus (HCV) RNA levels provides crucial insights into viral pathogenesis and antiviral therapy effects.
- Understanding viral clearance rates and infected cell lifespans aids in optimizing treatment strategies.
Purpose of the Study:
- To analyze the application of mathematical modeling in understanding HCV RNA dynamics during antiviral therapy.
- To elucidate how modeling informs estimations of viral production, drug resistance, and treatment effectiveness.
Main Methods:
- Utilizing mathematical models to analyze viral RNA decline kinetics in patients undergoing antiviral treatment.
- Deducing viral production rates, HCV-infected cell lifespan, and drug efficacy from observed viral load changes.
Main Results:
- Modeling allows estimation of pre-treatment viral production rates and the frequency of drug-resistant variant emergence.
- The effectiveness of antiviral agents and the lifespan of HCV-infected cells can be quantified through viral decline slopes.
- Existing models required revision to interpret RNA decline kinetics with direct-acting antiviral agents (DAAs).
Conclusions:
- Mathematical modeling is essential for understanding HCV treatment dynamics, including viral clearance and resistance.
- Revised modeling approaches are necessary for interpreting complex viral kinetics observed with modern DAAs.
- Further research is needed to resolve issues in combination DAA therapies, such as understanding sustained virologic response despite detectable RNA.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
257
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
01:25Hepatitis
46
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
46
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
340
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
340
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
313
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
313
01:16Hepatic Drug Excretion: Influencing Factors
748
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
748
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
347
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347